NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 2 Dec 2024
- Closes
- 13 Nov 2026, 23:59 UTC
- Value
- USD 350,000
- Reference
- PAR-25-269
- Location
- United States
- Sector
- Healthcare & Pharma
At a glance
National Institutes of Health in United States has published a funding call in healthcare & pharma: “NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)”. Submissions close on 13 November 2026, 18 days from today. The stated value is USD 350,000. Quote reference PAR-25-269 in any correspondence with the buyer. FreeTender has recorded 448 notices from this buyer since 2023, 379 of them currently open. There are 377 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.
Details
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive, Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Estimated total programme funding: USD 350000
CFDA number(s): 93.213
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 448 notices from National Institutes of Health, going back to May 2023 — 379 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 377 open Healthcare & Pharma tenders in United States. This one closes in 18 days.
More from this buyer
- NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)· closes 1 Dec
- Immune Tolerance Network (UM1 Clinical Trial Required)· closes 29 Jan
- Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)· closes 5 Mar
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)· closes 29 Jan
- National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)· closes 1 Nov
Similar Healthcare & Pharma tenders
- CMCS - Combined Synopsis-Solicitation - FCI Williamsburg· closes 10 Nov
- Request for Applications: Human-Scale AI Incubator Cohort (United States)
- 3D Image Reconstruction and Case Planning Services· closes 9 Nov
- RFP Preservation of the Force and Family POTFF III Support Contract H9240027RE001· closes 13 Nov
- Alaska VAHCS Police Psychological Testing and Evaluation· closes 30 Oct
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Закуп лекарственных средствТоварищество с ограниченной ответственностью "Национальный научный онкологический центр" · Kazakhstan
- Стол пеленальный.для филиала НАО "ГК "Правительство для граждан" по г.Алматы (ЦОН)Некоммерческое акционерное общество «Государственная корпорация «Правительство для граждан» · Kazakhstan
- Приобретение ультразвуковой системы (ДЦ)Государственное коммунальное предприятие на праве хозяйственного ведения "Городской диагностический центр" управления здравоохранения города Шымкент · Kazakhstan
- Закуп медицинской ультразвуковой моечной станцииКоммунальное государственное предприятие на праве хозяйственного ведения "Городской перинатальный центр" Управления общественного здравоохранения города Алматы · Kazakhstan
- Ванна водолечебная в комплекте КЗФНекомерческое акционерное общество "Национальный центр детской реабилитации" · Kazakhstan
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →